CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:	PRODUCT NAME:	
Strength:		
Lot Number:		
Expiration Date:		
CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Sample Size		
THC by Mass		
HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		

Lead

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	
RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

- 1. The hemp extract is the product of a batch tested by the independent testing laboratory;
- 2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
- 3. The batch does not contain contaminants unsafe for human consumption.[†]

 † Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

${\it Anresco\ Laboratories\ Sample\ ID\ \#:}$

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

Prepared By / Date Approved By / Date Status Docusing red is document (On-Feb-2024_133.4PST)



February 08, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 552500 Sample No. 1192021

SAMPLE INFORMATION

Description FP-24-0016 plusCBD 1.86floz 2000mg peppermint liquid SKU 123 exp 01/26

Lot Number CVSMGBP60011224

Category (Type) Non-Inhalable Edible (Tincture)

Received February 06, 2024

ANALYTICAL RESULTS

Analysis Pesticide Screen Pesticide Screen

Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem

Mass Spectrometry (GC-MS/MS)

Method MF-CHEM-13

Analysis Date February 06, 2024 to February 08, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.02	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.02	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.02	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **2** Report ID: T-4

Sample #: 1192021 **Batch #:** CVSMGBP60011224



Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.02	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by **Anresco, Inc.**



February 08, 2024

ND = None Detected BLOQ = Below Limit of Quantitation LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 **Sample #:** 1192021 **Batch #:** CVSMGBP60011224



February 08, 2024

CV SCIENCES, INC. 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 552500 Sample No. 1192021

SAMPLE INFORMATION

Description FP-24-0016 plusCBD 1.86floz 2000mg peppermint liquid SKU 123 exp 01/26

Lot Number CVSMGBP60011224

Category (Type) Non-Inhalable Edible (Tincture)

Received February 06, 2024

ANALYTICAL RESULTS

Analysis Residual Solvent Screen Pass

Instrument Gas Chromatography Mass Spectrometry (GC/MS)

Method MF-CHEM-32

Analysis Date February 06, 2024 to February 08, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	Not Applicable	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by **Anresco, Inc.**

Alma Dorante OCTOBER 1

ND = None Detected BLOQ = Below Limit of Quantitation LOD = Limit of Detection LOQ = Limit of Quantitation

February 08, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2

Sample #: 1192021 Batch #: CVSMGBP60011224



February 08, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 552500 Sample No. 1192021

SAMPLE INFORMATION

Description FP-24-0016 plusCBD 1.86floz 2000mg peppermint liquid SKU 123 exp 01/26

Lot Number CVSMGBP60011224

Category (Type) Non-Inhalable Edible (Tincture)

Received February 06, 2024

ANALYTICAL RESULTS

Analysis Mycotoxins Screen Pass

Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem

Mass Spectrometry (GC-MS/MS)

Method MF-CHEM-13

Analysis Date February 06, 2024 to February 08, 2024

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by **Anresco, Inc.**

ND = None Detected BLOQ = Below Limit of Quantitation LOD = Limit of Detection

LOQ = Limit of Quantitation



February 08, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Sample #: 1192021 Batch #: CVSMGBP60011224



4439 Polaris Ave. Las Vegas, NV, 89103, US (702) 728-5180

Kaycha Labs

plusCBD 1.86floz 2000mg peppermint liquid SKU 123 exp 01/26 Matrix: Infused Product

Type: Tincture



Certificate of Analysis

Sample:LA40205002-001 Harvest/Lot ID: CVSMGBP60011224

Batch#: FP-24-0016

Laboratory License # 69204305475717257553

Sample Size Received: 2 units Total Amount: 49.6 units

Retail Product Size: 49.6 gram

Ordered: 02/02/24 Sampled: 02/05/24 Completed: 02/08/24

PASSED

Feb 08, 2024 | CV Sciences License # N/A

PRODUCT IMAGE







Pesticides













Pages 1 of 2



Testing NOT TESTED



MISC.

NOT TESTED

PASSED

unit = 1.86floz, 49.6g



Cannabinoid

Total THC

0.0290% Total THC/Container : 14.3840 mg



Total CBD

Total CBD/Container: 2178.9280 mg



Total Cannabinoids Total Cannabinoids/Container:

2223.5670 mg



Analyzed by: 877, 1526 Weight: **Extraction date** Extracted by: 02/06/24 08:47:55 2.8561q

Analysis Method : SOP.T.30.031.NV; SOP.T.40.031.NV Analytical Batch : LA004588POT

Instrument Used: LV-SHIM-003 Analyzed Date : N/A

Dilution: 400

Reagent: 031623.36; 020224.01; 061223.13; 061623.01 Consumables: 042c6; 265084

Pipette: LV-PIP-006; LV-PIP-015; LV-PIP-023

Reviewed On: 02/06/24 08:55:16 Batch Date: 02/05/24 17:07:19

Cannabinoid analysis utilizing Ultra High Performance Liquid Chromatography with UV Detection (UHPLC-UV). Method SOP.T.30.031.NV for sample preparation and SOP.T.40.031.NV for analysis. Total THC = d8-THC + d9-THC + 0.877 * THCA, Total CBD = CBD + 0.877 * CBDA

This report shall not be reproduced, unless in its entirety, without written approval from Kaycha Labs. This report is an Kaycha Labs certification. The results relate only to the material or product analyzed. Test results are confidential unless explicitly waived otherwise. Void after 1 year from test end date. Cannabinoid content of batch material may vary depending on sampling error. IC=In-control QC parameter, NC=Non-controlled QC parameter, ND=Not Detected, NA=Not Analyzed, ppm=Parts Per Million, ppb=Parts Per Billion. Limit of Detection (LoD) and Limit Of Quantitation (LoQ) are terms used to describe the smallest concentration that can be reliably measured by an analytical procedure. RPD=Reproducibility of two measurements. Action Levels are State determined thresholds variable based on uncertainty of measurement (UM) for the analyte. The UM error is available from the lab upon request.The "Decision Rule" for the pass/fail does not include the UM. The limits are based on NV regulations.

Kelly Zaugg

Lab Director

State License # L003 ISO 17025 Accreditation # ISO/IEC 17025:2017: 97164



Signature 02/08/24



4439 Polaris Ave. Las Vegas, NV, 89103, US (702) 728-5180

Kaycha Labs

plusCBD 1.86floz 2000mg peppermint liquid SKU 123 exp 01/26

Matrix: Infused Product Type: Tincture



Certificate of Analysis

PASSED

License #: N/A

Sample : LA40205002-001 Harvest/Lot ID: CVSMGBP60011224

Reviewed On: 02/08/24 11:52:30

Extracted by:

1798

Batch Date: 02/06/24 09:25:12

Batch#: FP-24-0016 Sampled: 02/05/24 Ordered: 02/05/24

Sample Size Received: 2 units Total Amount : 49.6 units Completed: 02/08/24 Expires: 02/08/25 Sample Method: SOP Client Method

Page 2 of 2

Reviewed On: 02/08/24 14:40:37

Batch Date: $02/05/24 \ 11:38:37$



Microbial



Heavy Metals

PASSED

LOQ	Units	Result	Pass / Fail	Action Level
		Not Present	PASS	
		Not Present	PASS	
1000	cfu/g	ND	PASS	99999
100	cfu/g	ND	PASS	999
100	cfu/g	ND	PASS	999
1000	cfu/g	ND	PASS	9999
1	CFU/g	ND	TESTED	
	1000 100 100 1000	1000 cfu/g 100 cfu/g 100 cfu/g 1000 cfu/g	Not Present Not Present 1000 cfu/g ND 100 cfu/g ND 100 cfu/g ND 100 cfu/g ND 1000 cfu/g ND	Not Present PASS

Extraction date: Extracted by: Analyzed by: 1396, 879, 1526 Weight: 1.0656a 02/06/24 09:30:13

Analysis Method: SOP.T.40.058.FL; SOP.T.40.059B

Analytical Batch: LA004593MIC

Instrument Used: LV-PCR-003A (Gene-Up) (Asp) $\textbf{Analyzed Date}: \, \mathbb{N}/\mathbb{A}$

 ${\bf Dilution: N/A}$

Reagent: 020224.R02 Consumables: ASP1838; IS1094 Pipette: LV-PIP-017; LV-PIP-019

Analyzed by: 1798, 1662, 879, 1526 1.0264a 02/06/24 11:01:16

Analysis Method: SOP.T.40.209.NV; SOP.T.40.208

Analytical Batch: LA004595TYM Reviewed On: 02/08/24 11:52:3
Instrument Used: Micro plating with Flower, Edibles, TincturesBatch Date: 02/06/24 09:40:45 **Reviewed On:** 02/08/24 11:52:28

 $\textbf{Analyzed Date:} \ \mathbb{N}/\mathbb{A}$ Dilution: N/A

Reagent: 020724.R03

Consumables: 33N4WX; 418322349C; 418323027A; 33NJ59

Pipette: LV-PIP-026; LV-PIP-046

Microbial testing is performed by a combination of agar and Petrifilm plating as well as PCR (Polymerase Chain Reaction) to test for Mold/Yeast, Total Aerobic Count, Enterobacteria, Coliforms, Salmonella, Pathogenic E Coli, and Aspergillus.

Metal	LOQ	Units	Result	Pass / Fail	Action Level
ARSENIC	0.1670	ppm	<loq< th=""><th>PASS</th><th>2</th></loq<>	PASS	2
CADMIUM	0.1670	ppm	<loq< th=""><th>PASS</th><th>0.82</th></loq<>	PASS	0.82
LEAD	0.1670	ppm	<loq< th=""><th>PASS</th><th>1.2</th></loq<>	PASS	1.2

<LOQ PASS MERCURY 0.1670 ppm Analyzed by: 879, 1387, 1526 Weight: Extraction date: Extracted by: 0.4981g 02/06/24 11:20:30

Analysis Method: SOP.T.30.081.NV; SOP.T.40.081.NV Analytical Batch: LA004584HEA

Instrument Used : ICPMS-2 Shimadzu Analyzed Date : 02/05/24 12:13:08

 $\label{eq:Reagent:062823.01;011124.R09;081423.48;010120.01} \textbf{Consumables:} \ 042c6; \ 251697$

Pipette: LV-BTD-020; LV-BTD-019

Heavy Metals screening is performed using ICP-MS (Inductively Coupled Plasma - Mass Spectrometry) using method SOP.T.30.081.NV and SOP.T.40.081.NV.

This report shall not be reproduced, unless in its entirety, without written approval from Kaycha Labs. This report is an Kaycha Labs certification. The results relate only to the material or product analyzed. Test results are confidential unless explicitly waived otherwise. Void after 1 year from test end date. Cannabinoid content of batch material may vary depending on sampling error. IC=In-control QC parameter, NC=Non-controlled QC parameter, ND=Not Detected, NA=Not Analyzed, ppm=Parts Per Million, ppb=Parts Per Billion. Limit of Detection (LoD) and Limit Of Quantitation (LoQ) are terms used to describe the smallest concentration that can be reliably measured by an analytical procedure. RPD=Reproducibility of two measurements. Action Levels are State determined thresholds variable based on uncertainty of measurement (UM) for the analyte. The UM error is available from the lab upon request. The "Decision Rule" for the pass/fail does not include the UM. The limits are based on NV regulations.

Kelly Zaugg Lab Director

State License # L003 ISO 17025 Accreditation # ISO/IEC 17025:2017: 97164



Signature 02/08/24

Certificate Of Completion

Envelope Id: 88D5D74A741544B19B00F2DBB9494122 Status: Completed Subject: FP-24-0016 plusCBD 1.86floz 2000mg peppermint liquid SKU 123 exp 01/26 lot CVSMGBP60011224 COA

Source Envelope:

Document Pages: 8 Signatures: 1 **Envelope Originator:** Certificate Pages: 5 Initials: 1 Vandana Kothari

AutoNav: Enabled

Envelopeld Stamping: Enabled

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

vandana.kothari@cvsciences.com IP Address: 64.207.219.135

Record Tracking

Status: Original Holder: Vandana Kothari Location: DocuSign

2/9/2024 9:31:53 AM vandana.kothari@cvsciences.com

Signer Events Signature Timestamp Vandana Kothari Sent: 2/9/2024 9:32:38 AM Vandana kothani vandana.kothari@cvsciences.com Resent: 2/9/2024 1:09:29 PM DIRECTOR OF QUALITY Viewed: 2/9/2024 1:09:52 PM CV Sciences - Part 11 Signed: 2/9/2024 1:10:33 PM Signature Adoption: Pre-selected Style Security Level: Email, Account Authentication Signature ID: (Required) 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253

With Signing Authentication via DocuSign password With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

Joseph Dowling Sent: 2/9/2024 1:10:34 PM Joseph Dowling joseph.dowling@cvsciences.com Viewed: 2/9/2024 1:33:43 PM Signed: 2/9/2024 1:34:28 PM

Security Level: Email, Account Authentication (Required)

Signature Adoption: Pre-selected Style Signature ID:

1FB51541-2DDF-4F85-A71F-F07E156C6F48

Using IP Address: 107.132.215.12

With Signing Authentication via DocuSign password

With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Accepted: 2/9/2024 1:33:43 PM

ID: 026492d6-ca67-4f83-8f81-858a87c9eade

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp		
Notary Events	Signature	Timestamp		
Envelope Summary Events	Status	Timestamps		
Envelope Sent	Hashed/Encrypted	2/9/2024 9:32:38 AM		
Envelope Updated	Security Checked	2/9/2024 1:04:58 PM		
Envelope Updated	Security Checked	2/9/2024 1:04:58 PM		
Certified Delivered	Security Checked	2/9/2024 1:33:43 PM		
Signing Complete	Security Checked	2/9/2024 1:34:28 PM		
Completed	Security Checked	2/9/2024 1:34:28 PM		
Payment Events	Status	Timestamps		
Electronic Record and Signature Disclosure				

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, CV Sciences - Part 11 (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact CV Sciences - Part 11:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: vandana.kothari@cvsciences.com

To advise CV Sciences - Part 11 of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at vandana.kothari@cvsciences.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from CV Sciences - Part 11

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with CV Sciences - Part 11

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify CV Sciences Part 11 as described above, you consent to
 receive exclusively through electronic means all notices, disclosures, authorizations,
 acknowledgements, and other documents that are required to be provided or made
 available to you by CV Sciences Part 11 during the course of your relationship with CV
 Sciences Part 11.